Heat Biologics Granted Type C Meeting with FDA to Discuss Registrational Pathway for HS-110 in Combination with Opdivo(R) as a Treatment for Non-Small Cell Lung Cancer Sep 12, 2017
Heat Biologics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York Sep 7, 2017
Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award Jun 28, 2017
Heat Biologics Presents Poster on its Phase 2 Trial Evaluating HS-410 at ASCO Annual Meeting Jun 5, 2017
